Product Information
CEFDINIR 250 MG/5 ML SUSP is a generic product labeled by Ascend Laboratories, LLC, priced at $0.1176 per ML under NDC 67877054898. Its NADAC has been published 275 times since Jun 30, 2021.
FDA first approved this application on Feb 19, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/5mL
Manufacturer
Ascend Laboratories, LLCNDC
67877054898
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEFDINIRApproval Type
Generic (ANDA)
FDA Application
ANDA210534FDA Approved
2/19/2021
TE Code
AB
On Market Since
2/20/2021
Pharmacological Classes
Price Statistics
The NADAC for CEFDINIR 250 MG/5 ML SUSP has been published 275 times since Jun 30, 2021, and over the history we have for it it has declined 33.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1176 per ML |
|---|---|
| All-time high | $0.2347 (Apr 12, 2023) |
| All-time low | $0.1148 (Nov 20, 2024) |
| 52-week high | $0.1363 |
| 52-week low | $0.1176 |
| Median price | $0.1490 |
| Average price | $0.1553 |
| Largest weekly change | +39.7% (Feb 1, 2023) |
| Weeks tracked | 275 |
| Tracking since | Jun 30, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cefdinir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFDINIR 250 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CEFDINIR 250 MG/5 ML SUSP, manufactured by Ascend Laboratories, LLC, is $0.1176 per ML (NDC 67877054898), effective Sep 30, 2026.
How has the price of CEFDINIR 250 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for CEFDINIR 250 MG/5 ML SUSP has declined 33.3%. It has been tracked across 275 weekly CMS publications since Jun 30, 2021.
What are the highest and lowest recorded NADAC prices for CEFDINIR 250 MG/5 ML SUSP?
Since Jun 30, 2021, the NADAC for CEFDINIR 250 MG/5 ML SUSP has ranged from a low of $0.1148 (Nov 20, 2024) to a high of $0.2347 (Apr 12, 2023), with a median of $0.1490 per ML.
Are there cheaper alternatives to CEFDINIR 250 MG/5 ML SUSP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CEFDINIR 250 MG/5 ML SUSP, is $0.1100 per ML — about 6% below CEFDINIR 250 MG/5 ML SUSP.
Who manufactures CEFDINIR 250 MG/5 ML SUSP?
CEFDINIR 250 MG/5 ML SUSP (NDC 67877054898) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.